Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on September 11, 2023. The report discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
On September 11, 2023, the Board of Directors appointed Eric Bjerkholt as Chief Financial Officer, effective immediately. Mr. Bjerkholt previously served as CFO of Chinook Therapeutics, Inc. (2020-2023) and Aimmune Therapeutics, Inc. (2017-2020).
Compensation and Severance Arrangements
- Base Salary: $485,000 annually.
- Performance Bonus: Target of 40% of base salary, pro-rated for 2023.
- Equity Awards:
- Options to purchase 110,000 shares (vesting over 4 years: 25% at one year, remainder monthly).
- Restricted Stock Units (RSUs) for 55,000 shares (vesting over 3 annual installments).
- Severance (Without Cause/Good Reason - Outside Change in Control): 9 months of base salary, 12 months of accelerated equity vesting, and 9 months of healthcare coverage.
- Severance (Without Cause/Good Reason - During Change in Control): 18 months of base salary, 150% of target bonus, full acceleration of equity vesting, and 18 months of healthcare coverage.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 110,000 stock options granted to the new CFO.
- Review the specific definitions of "cause," "good reason," and "change in control" in the Severance Plan to understand potential payout triggers.
- Confirm the pro-rated bonus calculation for the remainder of the 2023 fiscal year.
- Assess the impact of the new CFO's background on the company's financial reporting and investor relations strategy.